Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
New England Journal of Medicine · 02.03.2023 · 388 (9) · 813-823
DOI: 10.1056/nejmoa2211437 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 02.03.2023. Verfasst von Sapna P Patel und 52 weiteren Autor:innen. Beteiligte Einrichtung: From the University of Texas M.D. Anderson Cancer Center, Houston (S.P.P., M.I.R., V.G.P.), and the University of Texas Health Science Center at San …. Hauptthemen laut MEDLINE: Melanoma, Neoadjuvant Therapy, Skin Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 920-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Merck, National Cancer Institute.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the University of Texas M.D. Anderson Cancer Center, Houston (S.P.P., M.I.R., V.G.P.), and the University of Texas Health Science Center at San Antonio, San Antonio (M.S.); Southwest Oncology Group Statistics and D…
ORCID-Profile: Sapna P Patel, Richard C Wu, Victor G Prieto, Michael C Lowe
Förderung
- NCI NIH HHS
- Merck
- National Cancer Institute
Zitieren
APA
Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., Hu-Lieskovan, S., Lao, C. D., Fecher, L. A., Truong, T. G., Eisenstein, J. L., Chandra, S., Sosman, J. A., Kendra, K. L., Wu, R. C., Devoe, C. E., Deutsch, G. B., Hegde, A., Khalil, M., …, & Ribas, A. (2023). Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. New England Journal of Medicine, 388(9), 813-823. https://doi.org/10.1056/nejmoa2211437
Vancouver
Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR, et al. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. New England Journal of Medicine. 2023;388(9):813-823. doi:10.1056/nejmoa2211437
BibTeX
@article{Patel2023,
author = {Patel, Sapna P and Othus, Megan and Chen, Yuanbin and Wright, G Paul and Yost, Kathleen J and Hyngstrom, John R and Hu-Lieskovan, Siwen and Lao, Christopher D and Fecher, Leslie A and Truong, Thach-Giao and Eisenstein, Jennifer L and Chandra, Sunandana and Sosman, Jeffrey A and Kendra, Kari L and Wu, Richard C and Devoe, Craig E and Deutsch, Gary B and Hegde, Aparna and Khalil, Maya and Mangla, Ankit and Reese, Amy M and Ross, Merrick I and Poklepovic, Andrew S and Phan, Giao Q and Onitilo, Adedayo A and Yasar, Demet G and Powers, Benjamin C and Doolittle, Gary C and In, Gino K and Kokot, Niels and Gibney, Geoffrey T and Atkins, Michael B and Shaheen, Montaser and Warneke, James A and Ikeguchi, Alexandra and Najera, Jose E and Chmielowski, Bartosz and Crompton, Joseph G and Floyd, Justin D and Hsueh, Eddy and Margolin, Kim A and Chow, Warren A and Grossmann, Kenneth F and Dietrich, Eliana and Prieto, Victor G and Lowe, Michael C and Buchbinder, Elizabeth I and Kirkwood, John M and Korde, Larissa and Moon, James and Sharon, Elad and Sondak, Vernon K and Ribas, Antoni},
title = {Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma},
journal = {New England Journal of Medicine},
year = {2023},
volume = {388},
number = {9},
pages = {813--823},
doi = {10.1056/nejmoa2211437}
}
EUVIMED